(Total Views: 474)
Posted On: 08/21/2019 8:42:02 PM
Post# of 154867
What the company pays Pourhassan is after all our money Misiu.
It should not be spent foolishly on his outlandish salary at a time when the company is running on fumes.
I truly hopes Pourhassan proves me wrong on his competence, and some of his promises regarding non-dilutive financing and partnerships, among other things, eventually turn out to be true.
However, until that happens, Pourhassan's compensation should reflect that befitting a 40 cent clinical stage biopharma that has been forced to live off of dilutive Paulson financing for many years.
And would it hurt Pourhassan to invest some of his $1.5M compensation in company stock, along with us shareholders?
While I believe the company would do much better under the tutelage of a more experienced and competent CEO, while we are stuck with Pourhassan, he should at least be paid a reasonable salary, which $1.5M clearly is not.
Thank you for your continued input, and words of medical wisdom.
LM
It should not be spent foolishly on his outlandish salary at a time when the company is running on fumes.
I truly hopes Pourhassan proves me wrong on his competence, and some of his promises regarding non-dilutive financing and partnerships, among other things, eventually turn out to be true.
However, until that happens, Pourhassan's compensation should reflect that befitting a 40 cent clinical stage biopharma that has been forced to live off of dilutive Paulson financing for many years.
And would it hurt Pourhassan to invest some of his $1.5M compensation in company stock, along with us shareholders?
While I believe the company would do much better under the tutelage of a more experienced and competent CEO, while we are stuck with Pourhassan, he should at least be paid a reasonable salary, which $1.5M clearly is not.
Thank you for your continued input, and words of medical wisdom.
LM
(0)
(0)
The Lawman
style="color:red">The Lawman"color:red">The Lawman:red">The LawmanThe Lawmanspan>Lawmanawmanimg]
